ASCO 2021 | APROMISS: catequentinib in synovial sarcoma

Brian Van Tine, MD, PhD, Washington University School of Medicine in St.Louis, St Louis, MO, summarizes the results of the Phase III APROMISS trial (NCT03016819), which assessed catequentinib, a tyrosine kinase inhibitor (TKI), in patients with metastatic or advanced synovial sarcoma. Patients received either catequentinib or dacarbazine, with catequentinib significantly improving progression-free survival (PFS). Prof. Van Tine additionally discusses the ongoing Phase II trial (NCT04551430) of cabozantinib, ipilimumab and nivolumab in patients with metastatic soft tissue sarcoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.